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Abstract
Stage III non-small cell lung cancer (NSCLC) is a very heterogeneous disease that encompasses patients with resected, 
potentially resectable and unresectable tumours. To improve the prognostic capacity of the TNM classification, it has been 
agreed to divide stage III into sub-stages IIIA, IIIB and IIIC that have very different 5-year survival rates (36, 26 and 13%, 
respectively). Currently, it is considered that both staging and optimal treatment of stage III NSCLC requires the joint work 
of a multidisciplinary team of expert physicians within the tumour committee. To improve the care of patients with stage III 
NSCLC, different scientific societies involved in the diagnosis and treatment of this disease have agreed to issue a series of 
recommendations that can contribute to homogenise the management of this disease, and ultimately to improve patient care.
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Introduction
In the 8th edition of the TNM classification proposed by 
the International Association for the Study of Lung Cancer 
(IASLC), accepted by the Union for International Cancer 
Control (UICC) and the American Joint Committee on Can-
cer (AJCC), stage III non-small cell lung cancer (NSCLC) 
encompasses patients who, in the absence of metastatic 
disease (M0), present N2 or N3 disease, a tumour with T4 
characteristics or one classified as T3 N1 [2] (Table 1). It is, 
therefore, a very heterogeneous definition, which includes 
patients with resected, potentially resectable and unresect-
able tumours.
To improve the prognostic capacity of the 8th edition of 
the TNM classification compared to the previous one, certain 
modifications have been carried out, focusing mainly on: (a) 
defining the T category that has been regrouped based on the 
tumour diameter, with 1-cm increment in size between T1a, 
T1b, T1c, T2a and T2b; T3 for 5‒7-cm tumours, and T4 for 
tumours larger than 7 cm. A tumour is considered T2 when 
there is main bronchial involvement that does not reach the 
main carina or partial/total atelectasis/pneumonitis, and 
T4 when there is invasion of the diaphragm [1, 2]; and (b) 
dividing stage III into sub-stages IIIA, IIIB and IIIC, since 
survival rates between stages are significantly different, with 
5-year survival of 36, 26 and 13%, respectively [2, 3].
Staging and treatment of stage III NSCLC requires mul-
tidisciplinary management by expert physicians, and evalu-
ation by cancer committees is essential. Given the hetero-
geneity of stage III NSCLC, the scientific societies involved 
in this work (Grupo Español de Cáncer de Pulmón [GECP], 
Sociedad Española de Cirugía Torácica [SECT], Sociedad 
Española de Medicina Nuclear e Imagen Molecular [SEM-
NIM]; Sociedad Española de Oncología Médica [SEOM]; 
Sociedad Española de Oncología Radioterápica [SEOR]; 
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Sociedad Española de Neumología y Cirugía Torácica 
[SEPAR] and Sociedad Española de Radiología Médica 
[SERAM]) have developed this consensus statement to 
homogenise its treatment and, ultimately, improve the care 
of patients with stage III NSCLC.
Staging of stage III NSCLC
Non‑invasive staging
Correct clinical staging is essential to manage patients with 
lung cancer. The first steps in the study of a possible thoracic 
neoplasm are the clinical history and a chest X-ray [4]. Fur-
ther examinations should then be carried out to determine 
the local and distant involvement of the neoplasm. Com-
puted tomography (CT) with intravenous contrast is the 
preferred technique in the study of lung cancer [2, 5], and 
it should include the entire thorax and upper abdomen. It is 
not necessary to cover a larger area of the abdomen, since it 
does not significantly increase the accuracy of staging [6]. 
Positron-emission tomography (PET) with the glucose ana-
logue 18F-FDG and especially, PET/CT with 18F-FDG, have 
revolutionised the staging of lung cancer.
T staging by CT will be indicated by the size of the main 
tumour, and this is one of the prognostic factors [2]. How-
ever, the degree of invasion of the mediastinal structures or 
the chest wall modifies the value of the T descriptor, as it 
impacts prognosis [7]. CT allows assessing the invasion of 
mediastinal vascular structures, although other techniques 
such as ultrasound or magnetic resonance imaging (MRI) 
have better results than CT when assessing the infiltration 
of the parietal pleura and the chest wall [1, 8]. In the pre-
operative assessment of Pancoast tumours, MRI plays a fun-
damental role, with better results than CT scans [9].
When assessing mediastinal lymph node involvement, 
PET/CT with 18F-FDG also plays a key role, with better 
results than CT [10–14]. However, its sensitivity is dimin-
ished in lymph nodes that are smaller than 10 mm in its 
short axis [15].
Initially, the presence of metastasis will be ruled out by 
cytohistological confirmation of suspicious lesions and pos-
sible extrathoracic lymph nodes that can classify the tumour 
as N3. A fine-needle aspiration (FNA) or an ultrasound-
guided core-needle biopsy (CNB) can also be used [16, 17].
The initial scans should include the organs with the great-
est potential of lung cancer metastases. One of the major 
contributions of PET/CT with 18F-FDG in the initial diag-
nosis of lung cancer is the detection of previously unknown 
metastases, with the consequent change in staging [18].
Brain MRI is indicated in patients with lung tumours who 
are going to be treated with curative intent, to screen for 
brain M1 [19]. Brain MRI is superior to CT [20] and to 
PET/CT [21].
Non‑surgical intrathoracic invasive staging
In the case of already diagnosed intrathoracic tumours, stage 
III (N2 or N3) will be established without requiring patho-
logical confirmation when there is an extensive mediastinal 
infiltration (bulky disease) [22].
In central tumours or those with enlarged hilar and medi-
astinal lymph nodes, the tumoral nature of the lymph nodes 
should be confirmed. An endobronchial ultrasound (EBUS)-
guided puncture will be performed since the positive and 
negative predictive values (PPV and NPV, respectively) of 
CT or PET are insufficient. EBUS would provide access to 
enlarged paratracheal, posterior tracheal, subcarinal, hilar, 
interlobar and lobar lymph nodes; and/or an endoscopic 
ultrasound (EUS) with access to paratracheal, subcarinal, 
paraesophageal and pulmonary ligament lymph nodes. Both 
techniques have a sensitivity close to 90% and a specificity 
of 100% [17, 22–25]. However, if the result is negative, not 
assessable or not sufficiently reliable (NPV: < 90%), staging 
must be completed with surgical techniques [24, 26, 27].
Peripheral thoracic tumours without nodal disease require 
mediastinal invasive staging if not subsolid and with a diam-
eter greater than 3 cm [28], since in these cases the possi-
bility of finding occult N2 nodes exceeds 10% [22–24, 28] 
(Fig. 1).
Table 1  Stage IIIA in the 8th 
TNM classification of lung 
cancer
See the definition of the T, N 
and M descriptors in Goldstraw 
et al. [3]
T N M
Stage IIIA
 T1a N2 M0
 T1b N2 M0
 T1c N2 M0
 T2a N2 M0
 T2b N2 M0
 T3 N1 M0
 T4 N0 M0
 T4 N1 M0
Stage IIIB
 T1a N3 M0
 T1b N3 M0
 T1c N3 M0
 T2a N3 M0
 T2b N3 M0
 T3 N2 M0
 T4 N2 M0
Stage IIIC
 T3 N3 M0
 T4 N3 M0
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Invasive surgical staging
Invasive surgical mediastinal staging should be performed 
when the result of non-surgical invasive techniques is nega-
tive or non-assessable. Despite the greater morbidity and 
mortality, these methods are the standard of excellence of 
mediastinal staging, having a higher NPV (Table 2).
Transcervical mediastinoscopy
In the transcervical mediastinoscopy, a biopsy should be 
performed at a minimum number of nodal stations (#4R, 
#4L and #7), as well as at stations #2R and #2L if they can 
be identified. Complications are scarce, with most being 
mild, and mortality is practically non-existent [29].
Extended cervical mediastinoscopy
Extended cervical mediastinoscopy is performed through the 
same incision of conventional mediastinoscopy and allows 
exploring the paraaortic and aortopulmonary window (#5 
and #6) in the tumours of the left upper lobe, which are not 
accessible through conventional mediastinoscopy.
Left parasternal mediastinotomy
In the left parasternal mediastinotomy, stations #5 and #6 
are explored through a second incision in the second left 
parasternal intercostal space.
Fig. 1  Performance algorithm for the staging of NSCLC* [17]. *The 
pathways leading to the diagnosis of stage III are highlighted in red. 
CT computed tomography, NSCLC non-small cell lung cancer, EBUS 
endobronchial ultrasound, EUS endoscopic ultrasound, PET positron-
emission tomography, PET/CT with 18F-FDG PET/CT with 18F 
fluorodeoxyglucose, NMR nuclear magnetic resonance, X-ray–CT 
X-ray–computed tomography, NPV negative predictive value
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Mediastinum pleuroscopy
Mediastinum pleuroscopy is indicated when lymph node (N) 
and pleural (M) dissemination should be ruled out. Unlike 
all the other explorations, this technique should be per-
formed with single-lung ventilation [30, 31].
Videothoracoscopy
The main advantage of videothoracoscopy is that it allows 
the exploration of the lower stations (#8, #9), but requires 
single-lung ventilation. It is also useful in the pre-operative 
staging of the T descriptor, as it can identify unresectable 
tumours that are not detected with imaging tests [32].
Video‑assisted mediastinal lymphadenectomy (VAMLA)
The objective of VAMLA is the lymphadenectomy of those 
stations that can be accessed through mediastinoscopy (#4R, 
#4L, #7, #2R, #2L).
Transcervical‑extended mediastinal lymphadenectomy 
(TEMLA)
TEMLA provides the opportunity for a much wider lym-
phadenectomy to the lower stations except for station #9. 
Morbidity and mortality are higher than in a conventional 
mediastinoscopy.
Methods of restaging after induction
Imaging studies
Although the usefulness of CT in restaging is uncertain, it 
has been observed that the response to neoadjuvant treatment 
by CT scan predicts a higher survival rate [33]. CT-based 
complete response has a high predictive value for complete 
pathological response, although it tends to underestimate it 
[34]. PET with 18F-FDG offers good results when assessing 
the treatment response of the primary tumour and metastases, 
although it is less accurate in the assessment of the mediastinal 
response, with a false negative rate of 20% and a false positive 
rate of 25% [35]. As a prognostic factor, the degree of reduc-
tion of the standardized uptake value (SUV) in the primary 
tumour may be predictive of survival and of the pathological 
response to treatment [36–38].
Cytohistological confirmation studies
Re-evaluation usually starts with the same techniques used 
for initial staging.
Non‑invasive or minimally invasive techniques
Bronchoscopy is reserved to confirm local tumour progression. 
Transbronchial needle aspiration (TBNA) achieves a correct 
diagnosis in 71% of patients and avoids other invasive proce-
dures in 35% of cases [39]. The use of FNA by EBUS or EUS 
in restaging has a sensitivity lower than 80%, with an NPV 
lower than this value [40–42]. Using both EBUS and EUS 
combined does not improve these results [43, 44]. When the 
results of EBUS and/or EUS do not show malignancy, it is 
recommended to use a surgical technique to reduce the propor-
tion of false negatives [26, 45].
Surgical techniques
The first mediastinoscopy can be reserved for restaging 
when N2 is initially confirmed by TBNA, EBUS or EUS 
during the initial staging.
Re-mediastinoscopy is technically more complex. It 
shows a sensitivity higher than 60% (range 60–74%), a 
specificity of 100%, an accuracy greater than 80% (range 
80–92%), a PPV of 100% and a NPV of 73% (range 73–86%) 
[46–48].
There are no restaging cases using VAMLA. As for 
TEMLA, authors present a restaging series with a sensitivity 
Table 2  Main invasive surgical 
techniques for stage III NSCLC 
staging
NSCLC Non-small cell lung cancer, TEMLA transcervical-extended mediastinal lymphadenectomy, 
VAMLA video-assisted mediastinal lymphadenectomy, NPV negative predictive value, PPV positive predic-
tive value
Technique Patients Sensitivity (%) Specificity (%) NPV (%) PPV (%)
Transcervical mediastinoscopy [130] 1362 86 100 > 94 100
Extended cervical mediastinoscopy [131] 221 67 100 94 100
Left parasternal mediastinotomy [132] 45 86 100 89 100
Videothoracoscopy [133] 55 100 100 100 100
VAMLA [134] 144 94 100 – 100
TEMLA [135] 698 96 100 99 100
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of 95%, an NPV of 97%, an accuracy of 98% and a specific-
ity and PPV of 100% [49]. Finally, there is only one study 
that uses videothoracoscopy as a restaging method [50] 
with a sensitivity of 83%, a NPV of 64% and a specificity 
of 100%.
Pre‑treatment functional assessment
Pre‑operative functional assessment
Before surgery, it is necessary to check patient’s heart func-
tion with patient’s history and heart medication revision. 
It is also necessary to check if they have a thoracic revised 
cardiac risk index value that does not exceed 1.5 points [51]. 
The patient must be referred for a cardiology consultation 
if necessary.
To assess the risk derived from pulmonary resection, a 
pulmonary function study should be performed. This study 
should calculate the maximum expiratory volume in the first 
second of forced expiration (FEV1) and the diffusion capac-
ity of the lung for carbon monoxide (DLCO) planned in the 
post-operative period (ppoFEV1 and ppoDLCO) [51–53]. 
When both indexes are greater than 60% of their theoretical 
values, the patient presents low risk and does not require 
further studies [51]. When the ppoFEV1 or the ppoDLCO 
is less than 30%, a cardiopulmonary exercise testing (CPET) 
will be indicated to quantify maximum oxygen consumption 
 (VO2max). If this is lower than 10 mL/kg/min (or less than 
35% of its theoretical value), the surgical risk is high. If the 
value is between 10 and 20 mL/kg/min (between 35 and 
75% of the theoretical value) the risk is intermediate, and 
if they are above the latter values the risk is low. When the 
ppoFEV1 or the ppoDLCO is less than 60% and both exceed 
30%, a CPET may be indicated, or stair climb/shuttle walk 
test may be used before CPET (Fig. 2) [51].
Pre‑radiotherapy functional assessment
Although there are no clearly defined FEV1 or DLCO limits 
for radiotherapy, the same criteria of surgical case series are 
used in most chemotherapy/radiotherapy clinical trials. Both 
the dosimetric parameters, the mean lung dose (MLD) and 
the percentage of healthy lung volume that receives at least 
20 Gy (V20) are effective tools to assess the risk of pulmo-
nary toxicity, although some studies support the importance 
of the clinical characteristics of patients in the estimation of 
lung damage secondary to radiation [54].
Multimodal management of stage III NSCLC
Incidental stage IIIA (N2)
The need for adjuvant treatment has been evidenced by 
the poor results of local control and overall survival (OS) 
after surgery in patients with stage IIIA NSCLC. Several 
randomised clinical trials and meta-analyses have shown a 
Fig. 2  Pre-operative functional assessment [51]. DLCO diffusing 
capacity of the lung for carbon monoxide, ppoDLCO planned post-
operatively DLCO, FEV1 forced expiratory volume in the first sec-
ond, ppoFEV1 planned post-operatively FEV1, CPET cardiopulmo-
nary exercise test, VO2max maximum oxygen consumption
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5% increase in OS at 5 years when administering adjuvant 
platinum-based chemotherapy [55, 56].
The role of post-operative radiotherapy (PORT) remains 
controversial. A first meta-analysis conducted in 1998 
showed a relative increase in the risk of death (21%), with a 
lower survival rate in patients receiving PORT [57]. How-
ever, a subsequent subgroup analysis established that this 
negative impact occurred in N0–N1 patients, although it was 
not clearly demonstrated in N2 patients. In several meta-
analyses and subsequent retrospective studies, PORT in N2 
patients reduced the risk of local relapse, without showing 
significant differences in OS [58–62]. However, since most 
of these studies were not performed with advanced radio-
therapy techniques, the validity of their results could be 
questioned. It is, therefore, a priority to obtain information 
from randomised trials with modern techniques to establish 
its real impact on OS [63].
Regarding the sequence of treatments, it is recommended 
to administer sequential treatment starting with chemother-
apy and to reserve concomitant treatment for patients with 
unresectable residual tumours, since adjuvant chemother-
apy–radiotherapy has not shown an increase in OS and there 
was a greater toxicity.
Potentially resectable stage IIIA (N2)
The group of patients with stage IIIA N2 NSCLC is hetero-
geneous and their treatment should be discussed in a mul-
tidisciplinary committee. For this purpose, the individual 
characteristics of the patient, such as age, lung function, 
comorbidity and functional status, must be considered before 
and after the induction therapy (Fig. 3).
The main objectives of induction therapy are: (a) to eradi-
cate subclinical metastases and mediastinal lymph node 
disease; (b) to improve local control of the disease; (c) to 
increase resectability; and (d) to reduce the magnitude of 
surgical resection.
The factors associated with a better prognosis in patients 
who undergo surgery are: confirmation of a complete 
response of the mediastinal (ypN0), achieving a complete 
resection and confirmation of a complete pathological 
response.
Induction chemotherapy
Several phase III studies have shown that platinum-based 
induction chemotherapy increases OS [64–71]. In stage IIIA 
(cN2) patients, induction chemotherapy increases OS com-
pared to surgery alone [67, 69, 72, 73]. These results have 
been confirmed in a subsequent meta-analysis [41].
Fig. 3  Algorithm for the clinical management of patients with stage IIIA-N2 NSCLC. NSCLC Non-small cell lung cancer, IHC immunohisto-
chemistry
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Induction chemoradiotherapy
The trials that analyse the role of treatment with induc-
tion chemoradiotherapy followed by surgery failed to show 
a survival benefit except in certain subgroups of patients 
[74–76]. A clinical trial randomised patients with resect-
able N2 disease (75% a single station affected) to receive a 
concomitant chemoradiotherapy treatment (radiation dose of 
45 Gy + cisplatin–etoposide) followed by surgery or radical 
radiotherapy (61 Gy). This trial showed a significant ben-
efit in progression-free survival (PFS) in favour of trimodal 
treatment, without significant differences in OS [74]. The 
lack of benefit in the surgery arm may be a consequence of a 
higher early mortality, especially in patients who underwent 
a pneumonectomy. A study in patients with resectable stage 
III NSCLC showed a benefit for induction chemotherapy 
in terms of the pathological response, and also an improve-
ment of the mediastinal stage, with no differences in survival 
rates [77].
A meta-analysis showed that the addition of radiotherapy 
to induction therapy does not increase survival [78], which 
raises questions about the need to add radiotherapy. It should 
be noted that several randomised studies have shown that 
mediastinal downstaging is associated with a better prog-
nosis [79].
Surgical treatment after induction
Surgical resection after induction therapy is indicated when 
imaging tests rule out extrathoracic disease progression, 
functional assessment after induction therapy indicates that 
the patient can tolerate resection, restaging techniques con-
firm an improvement of the mediastinal status and the type 
of resection ensures a complete resection, but avoids a pneu-
monectomy [74, 75].
The goal of surgical treatment after induction therapy 
is to achieve surgery with complete resection (R0). The 
R0 criteria defined by the IASLC include: (a) tumour-free 
resection margins confirmed microscopically; (b) system-
atic mediastinal lymph node dissection; (c) no extracapsu-
lar invasion of affected nodes; and (d) the most distal node 
resected should be free of disease [80].
There is some consensus that a minimum of six lymph 
nodes from three N2 stations should be analysed (always 
including station 7) [81–83]. An adequate lymphadenec-
tomy is considered a criterion for surgical quality [84, 85]. 
Surgical resection is not recommended if R0 surgery is not 
feasible, radical radiotherapy could be administered if not 
previously done [86].
Based on the results obtained in patients who underwent 
surgery after induction therapy and still had mediastinal 
lymph node involvement (ypN2), surgery can be an option 
despite the persistence of N2 involvement in very specific 
cases, such as initial disease confined to a station that is not 
enlarged (resectable stage IIIA-N2), with PET/CT with 18F-
FDG results showing minimal residual disease, with resec-
tion less than a pneumonectomy, and when R0 is feasible.
Adjuvant treatment with chemotherapy
Although adjuvant chemotherapy improves disease-free 
survival in R0 patients [87], no specific data support adju-
vant chemotherapy after induction therapy and surgery in 
initial stage IIIA-N2 NSCLC. Therefore, administration of 
adjuvant chemotherapy should be tailored for each patient, 
according to the pathological response and the pathology 
findings.
Adjuvant treatment with radiation therapy
Adjuvant radiotherapy therapy to the mediastinum is not 
recommended in pN0 or pN1 stage. When there is multiple 
hilar involvement, in extracapsular invasion or in pN2 stage, 
adjuvant radiotherapy may be considered if it has not been 
administered during induction therapy [88].
Administration of adjuvant radiotherapy to the T is not 
recommended in patients with surgery R0 and in the case of 
R1 or R2 surgery, adjuvant radiotherapy if not administered 
previously [88].
Unresectable stages IIIA (N2), IIIB and IIIC
Determination of unresectability in patients with stage 
III NSCLC must be determined by a multidisciplinary 
committee.
Treatment with concomitant chemotherapy/radiotherapy
Concomitant chemotherapy/radiotherapy is the treatment of 
choice for patients with a good general condition (ECOG 
0–1) and a weight loss of less than 5% in the previous 
3 months [89]. This is a radical treatment that aims to cure 
the disease. A platinum-based chemotherapy regimen is 
recommended [90]. Gemcitabine regimens are not recom-
mended because of higher pulmonary toxicity. The recom-
mended radiotherapy dose is 60–66 Gy [91]. Concurrent 
chemoradiotherapy provides a median OS of 22–25 months 
and a 5-year OS of 20% [92], with a grade 3 toxicity or 
higher consisting of oesophagitis (7–21%) and pneumonitis 
(3–7%) [93].
Treatment with sequential chemoradiotherapy
In patients with ECOG > 1, weight loss greater than 5% and 
a large volume to be irradiated with an unacceptable risk of 
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pneumonitis, the recommendation is to administer induction 
chemotherapy followed by radical radiotherapy.
Systemic treatment of stage III NSCLC
Adjuvant chemotherapy after stage IIIA (N2) 
incidental disease
Patients with N2 disease documented during surgery are 
candidates for adjuvant chemotherapy (level of evidence: 
I, recommendation grade: A). The recommended regimen 
in patients without contraindications is cisplatin doublet 
chemotherapy, since it has shown to improve OS in com-
plete resected patients. The recommended number of cycles 
is four (level of evidence: I, recommendation grade: A) [14]. 
Cisplatin–etoposide and cisplatin–vinorelbine are the plati-
num doublets with the greatest evidence, as shown in the 
LACE meta-analysis [56]. Carboplatin can be administered 
if there are contraindications for treatment with cisplatin.
Induction chemotherapy
Patients with potentially resectable IIIA-N2 disease can 
receive pre-operative treatment with chemotherapy, with 
or without radiotherapy, followed by surgery. The recom-
mended induction chemotherapy regimen in patients without 
contraindications is to administer three to four cycles of a 
cisplatin doublet, based on complementary chemotherapy 
studies (level of evidence: II, recommendation grade: B).
Neoadjuvant chemotherapy has been shown to improve 
OS. In a meta-analysis of 15 randomised studies, a signifi-
cant 5-year overall survival benefit of 5% was observed in 
patients at stage IB–IIIA (HR: 0.87; 95% CI 0.78–0.96; 
p = 0.007) [73].
Chemotherapy combined with radiotherapy
In patients with unresectable stage III NSCLC, the admin-
istration of chemotherapy concomitant with radiotherapy is 
recommended (level of evidence: I, recommendation grade: 
A) [73]. In patients in whom concomitant treatment is not 
possible, the alternative is a sequential administration.
The recommended chemotherapy regimen is a cisplatin 
regimen with vinorelbine or etoposide [89, 94]. Most ran-
domised studies comparing sequential versus concomitant 
treatment use cisplatin with etoposide or cisplatin with 
vinorelbine [92, 95]. It is recommended to administer two 
to four cycles of chemotherapy concurrent with radiotherapy 
(level of evidence I, recommendation grade: A) [89].
Cisplatin can be replaced by carboplatin in patients 
with comorbidities that contraindicate treatment with cis-
platin (carboplatin and paclitaxel is one of the most used 
regimens). In unresectable patients, cisplatin and peme-
trexed regimens have not shown better results than standard 
treatment with cisplatin and etoposide concomitant with 
radiotherapy [96].
Age does not justify administering a suboptimal treatment 
in elderly patients. Therefore, the most convenient treatment 
should be administered according to the patient’s illness and 
comorbidities (level of evidence: I, recommendation grade: 
A).
Radiotherapeutic treatment of stage III 
NSCLC
Radiotherapy volumes
Gross tumour volume (GTV) includes the primary tumour 
and the affected lymph nodes, when there is lymph node 
involvement. The clinical target volume (CTV) includes the 
GTV with a three-dimensional margin that incorporates the 
microscopic extension of the disease. The planning target 
volume (PTV) includes the CTV with a three-dimensional 
margin that considers the tumour movement and the uncer-
tainties in the patient’s daily positioning. Improving the 
immobilisation systems, respiratory movement control and 
image-guided radiation therapy (IGRT) can reduce the PTV 
margin [97].
Prophylactic irradiation of non-affected lymph node areas 
is not recommended, especially if PET/CT with 18F-FDG 
has been performed during staging, since it does not increase 
survival and causes more toxicity [98, 99].
When post-operative radiotherapy is administered, the 
CTV should include the bronchial stump and the ipsilateral, 
subcarinal and contralateral hilar and paratracheal nodal 
areas [60, 100].
A correct definition of the healthy organs is a priority 
to minimise side effects, especially respiratory and cardiac 
[101, 102]. A useful source is the RTOG volume contouring 
atlas [103].
New technological advances such as 4D radiotherapy, the 
use of PET/CT with 18F-FDG for the simulation, intensity-
modulated radiotherapy (IMRT) or volumetric-modulated 
arc therapy (VMAT), IGRT and the control of respiratory 
movement permit the administration of radical doses and 
reduce the impact on healthy organs, and should be used 
whenever available [104].
Radiotherapy dose
As part of a radical treatment, doses of 60–66 Gy at 2.0 Gy/
day are recommended. Higher doses do not improve results 
and increase side effects [91]. In the case of sequential 
radiation therapy, accelerated radiotherapy schemes should 
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be evaluated [105]. In post-operative irradiation, doses of 
50–54 Gy at 1.8–2.0 Gy/day are usually indicated, although 
higher doses may be administered when there is extracap-
sular involvement or involvement of resection margins [60]. 
If radiation therapy is administered as part of an induction 
therapy, doses of 45–54 Gy at 1.8–2.0 Gy/day are usually 
used. A team of experienced thoracic surgeons is required 
when administering higher doses as induction therapy to 
avoid possible post-operative complications [106, 107].
Surgical treatment of stage III NSCLC
Surgery in patients with stage IIIA and IIIB non-N3 NSCLC 
should be considered in a multidisciplinary approach, espe-
cially if the R0 is feasible without pneumonectomy [19, 81, 
82, 108–111]. The best results are obtained after an adequate 
selection of the optimal therapeutic scheme and when the 
surgery is performed at hospitals that have trained surgi-
cal teams with anaesthesiology, thoracic surgery, nursing, 
rehabilitation, etc. [81–83, 108, 109, 111].
It is important to assess the resectability of the lesion and 
the operability of the patient. As mentioned previously, there 
are updated guidelines for this purpose in which predictable 
ppoFEV1 and ppoDLCO values and oxygen consumption 
have a central role in decision-making. There is not a single 
value or scale (Thoracoscore, ThRCRI, etc.) that indicates 
operability. The determination of the patient’s general condi-
tion using the ECOG scale or the Karnofsky index as well as 
their expectations and socio-family environment will help to 
make individualised decisions regarding the surgical options 
[112, 113].
The standard anatomical resection is lobectomy or 
bilobectomy (level of evidence: I, recommendation grade: 
A). Anatomical segmental resection is considered in situa-
tions of impairment of the cardiopulmonary reserve. Pneu-
monectomy can be avoided, as far as possible, with bron-
choplastic and angioplastic resections, since this procedure 
(especially if it is right pneumonectomy) has a significant 
impact on the results [114, 115].
The setting for the surgical approach would be the least 
invasive one, such as muscle-sparing thoracotomies, video-
assisted thoracic surgery (VATS) or robot-assisted thoracic 
surgery (RATS). The purpose of this approach is to be the 
least aggressive possible and to manage these patients, who 
must necessarily receive neo- or coadjuvant treatments, 
safely. Anaesthetic and peri-operative care are crucial in 
the future for these patients [115]. In this context, there are 
multimodal rehabilitation protocols established, such as fast-
track or enhanced recovery after surgery (ERAS) [116].
Consolidation treatment in unresectable 
stage III NSCLC
Until recently, consolidation treatment with chemotherapy 
[92, 117], targeted therapy or some types of immunotherapy 
[118] failed to increase survival in patients with stage III 
NSCLC [119].
Recently, the administration of the anti-PD-L1 drug dur-
valumab as consolidation treatment for 1 year in patients 
with unresectable stage III NSCLC treated with radical 
chemoradiotherapy and with no progressive disease has 
been established as a new standard (level of evidence: I, 
recommendation grade: A). This is based on the results of a 
phase III clinical trial, in which durvalumab compared with 
placebo increased both the PFS (17.2 months vs. 5.6 months, 
respectively, HR, 0.51, 95% CI 0.41–0.63) and the 2-year 
overall survival of 66.3% (95% CI 61.7–70.4) with dur-
valumab to 55.6% (95% CI 48.9–61.8) with placebo (HR, 
0,68; 99.73% CI 0,47–0,997; p = 0.0025). The benefit was 
consistent in all the pre-specified subgroups. Durvalumab 
was well tolerated, with a 15.4% of treatment discontinua-
tion due to toxicity, and with grades 3–4 toxicity of 30.5% 
in patients treated with durvalumab and 26% of patients in 
the placebo group [120]. The European Medicines Agency 
(EMA) has approved durvalumab as a consolidation treat-
ment in patients with locally advanced or unresectable 
NSCLC with expression of PD-L1 ≥ 1% of tumour cells 
and whose disease has not progressed after platinum-based 
chemoradiotherapy, based on an unplanned post hoc analysis 
of PD-L1 expression.
Follow‑up of patients with stage III NSCLC
A key point in the follow-up of the patients diagnosed 
with a pulmonary neoplasm is quitting smoking, since this 
improves the prognosis of the disease [121]. Of note, it 
has been shown that a causal relationship may be inferred 
between smoking and increased mortality from any cause 
and mortality associated with cancer, as well as regarding 
the appearance of second lung neoplasms [121]. There is 
also a relationship, although it cannot be considered a cause, 
between smoking and an increased risk of recurrence, worse 
response to treatment and greater probability of suffering 
treatment-related toxicity [121].
The follow-up frequency of patients with lung cancer is 
controversial. SEOM and SERAM recommend that patients 
treated with surgery undergo follow-up with CT scan every 
6–12 months during the first 2 years, and annually thereafter 
[5, 122]. Some authors suggest that performing a PET/CT 
with 18F-FDG 1 year after surgery is more sensitive than CT 
alone to detect recurrence [123].
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Table 3  Recommendations for the clinical management of patients with stage III NSCLC
CT Computed tomography, DLCO diffusing capacity of the lung for carbon monoxide, EBUS endobronchial ultrasound, ECOG Eastern Coop-
erative Oncology Group, EUS endoscopic ultrasound, FEV1 forced expiratory volume in the first second, MRI magnetic resonance imaging, 
NSCLC non-small cell lung cancer, PET positron-emission tomography, PET/CT with 18F-FDG, OS overall survival, R0 complete resection
Non-invasive staging of stage III NSCLC:
CT scan of the thorax and upper abdomen with intravenous contrast is the preferred technique in the initial assessment when lung cancer is 
suspected
PET/CT with 18F-FDG is the most sensitive technique to explore mediastinal lymphadenopathy
 Brain MRI is indicated in patients with lung neoplasm who are going to be treated with curative intent
Invasive staging of stage III NSCLC:
Non-surgical invasive staging methods are the first choice due to their lower associated morbidity and mortality.
In cases in which the result of invasive non-surgical techniques is negative or non-assessable, surgical staging methods should be recommended, 
as they remain the standard of excellence in stage III NSCLC staging
Pre-treatment functional assessment:
Before conducting surgery on the patient, it is necessary to ensure that their cardiac function is adequate and to estimate the risk derived from 
pulmonary resection by means of a pulmonary function study
The FEV1 and the DLCO predicted after the scheduled surgery will be calculated
Functional assessment prior to radiotherapy is less defined, but the lung and heart doses should be minimised
Multimodal management of stage III NSCLC
Incidental Stage IIIA (N2):
In stage IIIA with incidental N2 involvement, the recommended treatment is surgical resection and adjuvant chemotherapy (level of evidence: I, 
recommendation grade: A)
The administration of sequential post-operative radiotherapy after completing chemotherapy has shown to increase local control of the disease, 
without being clear whether it provides an OS benefit (level of evidence: II, recommendation grade: C)
Potentially resectable stage IIIA (N2):
In potentially resectable stage IIIA-N2, initial surgical resection is not recommended (level of evidence: I, recommendation grade: A)
In potentially resectable stage IIIA-N2, the recommended treatment is induction chemotherapy, followed by surgery if there is improvement of 
the stage (level of evidence: I, recommendation grade: A), followed by adjuvant radiotherapy according to the findings after surgery (level of 
evidence: IV, recommendation grade: C)
 Neoadjuvant chemotherapy/radiotherapy achieves a greater downstaging of mediastinal disease volume with respect to induction chemotherapy, 
without an impact on OS (level of evidence: I, recommendation grade: C)
Unresectable stages IIIA (N2); IIIB and IIIC:
In patients with ECOG 0–1, without weight loss > 5% and with irradiation volumes that do not compromise cardiopulmonary functionality, the 
administration of concomitant platinum-based chemotherapy/radiotherapy is recommended (level of evidence: I, recommendation grade: A), 
followed by consolidation treatment with durvalumab, if there is no disease progression
The administration of radiotherapy at doses higher than 66 Gy is not recommended (level of evidence: I, recommendation grade: A)
Systemic treatment of stage III NSCLC
The recommended chemotherapy regimens, either adjuvant, induction or radical combined with radiotherapy, are cisplatin doublets
Radiotherapeutic treatment of stage III NSCLC:
The recommended radiotherapy dose in radical chemoradiotherapy is 60–66 Gy at 2 Gy/day. If administered sequentially, accelerated schemes 
that reduce the total duration of treatment are recommended
In post-operative irradiation, doses of 50–54 Gy at 1.8–2.0 Gy/day are recommended. In case of extracapsular involvement or resection margins, 
higher doses may be administered
In case of induction radiotherapy, doses of 45–54 Gy are usually used
Surgical treatment of stage III NSCLC:
The standard anatomical resection is lobectomy or bilobectomy (level of evidence: I, recommendation grade: A).
Surgery in patients with stage III NSCLC is considered in a multidisciplinary and personalised treatment environment, especially if R0 is feasi-
ble without pneumonectomy
This surgery should be carried out at hospitals that have trained surgical teams
Stage III NSCLC consolidation treatment:
Durvalumab is recommended as consolidation treatment for 1 year in patients with unresectable stage III NSCLC with expression of PDL1 ≥ 1% 
in tumour cells and without progression after radical chemoradiotherapy (level of evidence: I, recommendation grade: A)
Follow-up of patients with stage III NSCLC:
Quitting smoking should be advised to patients undergoing treatment for lung cancer
It is recommended to carry out a CT scan every 6–12 months during the first 2 years and later annually
PET/CT with 18F-FDG shows better results in the assessment of patients treated with chemoradiotherapy
The evaluation criteria for response to systemic treatments (RECIST, iRECIST) should be used according to the type of systemic therapy used
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In patients treated with radiotherapy or chemoradiother-
apy, an initial PET/CT with 18F-FDG and during follow-up 
is useful for predicting areas with greater potential for recur-
rence or treatment failure [124]. On the other hand, treat-
ment response can be assessed early with a post-treatment 
PET/CT with 18F-FDG [125–127].
The response assessment criteria will be established 
based on the systemic treatment received. In most cases, the 
RECIST 1.1 criteria will apply [128], but for patients who 
have received immunotherapy, iRECIST criteria should be 
used [129]. In these patients, successive controls should be 
carried out in the event of tumour growths, given the pos-
sibility of pseudoprogression. However, to verify that these 
are true progressions and not peritumoural inflammatory 
reactions, controls should not be performed before 4 weeks 
after the last assessment.
Conclusions
Stage III NSCLC is a very heterogeneous disease in which 
multidisciplinary management is essential. A multimodal 
approach is necessary when establishing treatment for stage 
III NSCLC. This will depend on the stage III subtype (inci-
dental, potentially resectable or unresectable), and may 
include surgery, chemotherapy and radiotherapy, as detailed 
in Table 3. Recently, consolidation therapy with durvalumab 
has become the new standard treatment for unresectable 
NSCLC after radical chemoradiotherapy and without dis-
ease progression.
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